Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
11/2012
11/01/2012US20120276143 Probiotic bifidobacterium strain
11/01/2012US20120276142 Nucleic acid sequences encoding and compositions comprising ige signal peptide and/or il-15 and methods for using the same
11/01/2012US20120276126 Lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
11/01/2012US20120276124 Maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
11/01/2012US20120276122 Methods for diagnosis and treatment of cellular proliferative disorders
11/01/2012US20120276112 Anti-factor xi monoclonal antibodies and methods of use thereof
11/01/2012US20120276111 Methods and compositions for treating conditions associated with angiogenesis using a vascular adhesion protein-1 (vap-1) inhibitor
11/01/2012US20120276108 Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
11/01/2012US20120276104 Multispecific modular antibody
11/01/2012US20120276102 Methods of treatment utiliziing binding proteins of the interleukin-21 receptor
11/01/2012US20120276101 Viral chemokine-antigen fusion proteins
11/01/2012US20120276100 Compositions and Methods of Use of Immunotoxins Comprising Ranpirnase (Rap) Show Potent Cytotoxic Activity
11/01/2012US20120276094 Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same
11/01/2012US20120276093 Therapeutic combination comprising a cdc7 inhibitor and an anti-neoplastic agent
11/01/2012US20120276091 Human Recombinant Monoclonal Antibody That Specifically Binds to VCAM-1 and Inhibits Adhesion and Transmigration Between Leukocytes and Endothelial Cells
11/01/2012US20120276090 Gene recombinant antibody and antibody fragment thereof
11/01/2012US20120276089 Antibodies That Inhibit WNT Signaling And Methods Of Using The Same
11/01/2012US20120276088 Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
11/01/2012US20120276086 Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
11/01/2012US20120276085 Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
11/01/2012US20120276082 Treatment of cancer
11/01/2012US20120276077 Therapeutic ribonucleases
11/01/2012US20120276070 Induced Pluripotent Stem Cells and Related Methods
11/01/2012US20120276066 Peptide Linked Cell Matrix Materials for Stem Cells and Methods of Using the Same
11/01/2012US20120276053 Oncolytic vaccinia virus cancer therapy
11/01/2012US20120276052 Transgene delivering retrovirus targeting collagen exposed at site of tissue injury
11/01/2012US20120276049 Methods and compositions for amelioration of autoimmune disease using fusion proteins of anti-dendritic cell receptor antibody to peptide sequences
11/01/2012US20120276046 Anti ganglioside gd3 antibodies and uses thereof
11/01/2012US20120276045 Treatment of solid cancers
11/01/2012US20120276010 Microorganisms for therapy
11/01/2012US20120276007 Imaging agents and methods of imaging naaladase or psma
11/01/2012US20120276004 Human myeloid derived suppressor cell cancer markers
11/01/2012US20120276001 Bifunctional polyazamacrocyclic chelating agents
11/01/2012US20120276000 Clec14a inhibitors
11/01/2012US20120275999 Oncolytic rhabdovirus
11/01/2012US20120275997 Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer
11/01/2012CA2834680A1 Selecting use of proteasome inhibitors based on nf-kb2 sequence
11/01/2012CA2834624A1 Il4/il13 binding repeat proteins and uses
11/01/2012CA2834404A1 Anti-cd40 antibodies and methods of use
11/01/2012CA2834282A1 Method of treating lymphoma using pyridopyrimidinone inhibitors of pi3k/mtor
11/01/2012CA2834224A1 17a-hydroxylase/c17,20-lyase inhibitors
11/01/2012CA2834166A1 Bicyclic pyridazine compounds as pim inhibitors
11/01/2012CA2834136A1 Anti-b7-h3 antibody
11/01/2012CA2833962A1 Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
11/01/2012CA2833615A1 Microrna compounds and methods for modulating mir-21 activity
11/01/2012CA2833592A1 Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
11/01/2012CA2833500A1 Lyophilized preparation of cytotoxic dipeptides
11/01/2012CA2833390A1 Hsp90 combination therapy
11/01/2012CA2832360A1 Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
11/01/2012CA2832342A1 Small molecule trail gene induction by normal and tumor cells as an anticancer therapy
11/01/2012CA2827952A1 Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
11/01/2012CA2826197A1 Pyrrolotriazinone derivatives as pi3k inhibitors
10/2012
10/31/2012EP2518149A1 HLA-A*3303-restricted WT1 peptide and pharmaceutical composition comprising the same
10/31/2012EP2518144A1 Aging marker, method for evaluating aging inhibitor, and cancer inhibitor
10/31/2012EP2518142A1 Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
10/31/2012EP2518086A1 Radiolabeled compound directable in vivo to target tissue and use thereof
10/31/2012EP2518083A2 Combination of angiopoietin-2 antagonist and of VEGF-A, KDR and/or FLTL antagonist for treating cancer
10/31/2012EP2518078A1 Method for manufacturing dimers and multimers by increasing the production of bond bridges in a complex of multiple monomers and repeating chains of an adherend of a type specifically adhering to monomers
10/31/2012EP2518074A1 Phosphoinositide 3-kinase inhibitor compounds and methods of use
10/31/2012EP2518071A1 Imidazopyridine derivatives as PI3K inhibitors
10/31/2012EP2518070A1 Pyrrolotriazinone derivatives as PI3K inhibitors
10/31/2012EP2518063A1 Pyridazinones and furan-containing compounds
10/31/2012EP2518056A1 Seven-membered ring compound and pharmaceutical use therefor
10/31/2012EP2517730A2 Vitamin receptor binding drug delivery conjugates
10/31/2012EP2517729A2 Vitamin receptor binding drug delivery conjugates
10/31/2012EP2517708A1 Method for predicting therapeutic effect of chemotherapy on hepatocellular carcinoma patient
10/31/2012EP2517707A1 Antitumor agent or postoperative adjuvant chemotherapeutic agent for treatment of hepatocellular carcinoma
10/31/2012EP2516470A1 Antibodies to non-functional oligomeric p2x7 receptors
10/31/2012EP2516469A1 Anti-her3 antibodies and uses thereof
10/31/2012EP2516468A1 Anti-flt3 antibodies and methods of using the same
10/31/2012EP2516465A1 Anti-bv8 antibodies and uses thereof
10/31/2012EP2516444A2 Heterocyclic compounds as janus kinase inhibitors
10/31/2012EP2516442A1 Pyrrolo[2,3-d]pyrazin-7-yl pyrimidine compounds
10/31/2012EP2516438A2 Compounds and methods for kinase modulation, and indications therefor
10/31/2012EP2516435A1 Inhibitors of akt activity
10/31/2012EP2516434A1 Fused heteroaromatic pyrrolidinones as syk inhibitors
10/31/2012EP2516433A1 Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors
10/31/2012EP2516431A1 Pyrrolopyridinyl-pyrimidin-2-ylamine derivatives
10/31/2012EP2516425A1 Aminopyrimidine kinase inhibitors
10/31/2012EP2516407A1 Radiopharmaceutical complexes
10/31/2012EP2516405A1 4-phenylamino-pyrimidine derivatives having protein kinase inhibitor activity
10/31/2012EP2516404A2 Preparation of bendamustine and its salts
10/31/2012EP2516398A2 Novel phenol derivatives and pharmaceutical or cosmetic use thereof
10/31/2012EP2516396A1 Therapeutic compounds
10/31/2012EP2516395A1 (methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
10/31/2012EP2516393A1 Carboxamide compounds and their use as calpain inhibitors
10/31/2012EP2516011A1 Carrier composition
10/31/2012EP2516010A2 Lipids, lipid compositions, and methods of using them
10/31/2012EP2516009A1 Substituted isoquinolinones and quinazolinones
10/31/2012EP2515949A1 Aldehydes for in vivo imaging of aldh in cancer stem cells
10/31/2012EP2515944A1 Methods and compositions related to annexin 1-binding compounds
10/31/2012EP2515930A1 Methods and compositions related to reduced met phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
10/31/2012EP2515916A1 Furin-knockdown and gm-csf-augmented (fang) cancer vaccine
10/31/2012EP2515914A1 Tyrosine bioconjugation through aqueous ene-like reactions
10/31/2012EP2515913A2 Use of vitamin d glycosides and sulfates for treatment of disease
10/31/2012EP2515904A2 Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
10/31/2012EP2515898A1 Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents
10/31/2012EP2515878A2 Sustained-release formulation
10/31/2012EP2515655A1 1h-pyrazolo[3,4-beta]pyridines and therapeutic uses thereof
10/31/2012EP2515650A1 Targeted radiolabeled compounds and their use for the treatment and diagnosis of cancer
1 ... 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 ... 2211